You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape

Article info

Article menu
Basic tumor immunology
Original research
circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape

Authors

  • Li-Feng Dong Department of Breast Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China PubMed articlesGoogle scholar articles
  • Fang-Fang Chen Department of Breast Surgery, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China PubMed articlesGoogle scholar articles
  • Yang-Fan Fan Department of Breast Surgery, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China PubMed articlesGoogle scholar articles
  • Kun Zhang Department of Breast Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China PubMed articlesGoogle scholar articles
  • Hui-Hui Chen Department of Breast Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China PubMed articlesGoogle scholar articles

Citation

Dong L, Chen F, Fan Y, et al
circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape
Journal for ImmunoTherapy of Cancer 2023;11:e005461. doi: 10.1136/jitc-2022-005461
Online issue publication 
June 22, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.